$BYFC

Insider Selling: Broadway Financial (NASDAQ:BYFC) Director Sells $81,012.00 in Stock

Broadway Financial director Wayne-Kent Bradshaw sold 8,600 shares of BYFC on May 26 at an average $9.42, for about $81,012, according to an SEC filing. After the sale, he held 33,359 shares. BYFC reported Q1 EPS of $0.04 on $9.42M revenue (Mar. 31). Weiss Ratings kept a Sell stance, upgrading to “Sell (d+)”.

Original reporting
Published May 30, 2026, 10:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 30, 2026, 11:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Insider Selling: Broadway Financial (NASDAQ:BYFC) Director Sells $81,012.00 in Stock — source image
Decision brief

The 30-second read

$BYFCBearishMed
01

Why it matters

The immediate tradable element is the insider sale disclosure; it may influence short-term sentiment for BYFC, but without new guidance or a credit/regulatory catalyst, conviction should be tempered.

02

Market read

A disclosed director sale and a still-cautious Sell consensus can nudge near-term sentiment, while the lack of new fundamentals limits directional follow-through.

03

What to watch

The article doesn’t quantify whether the director sold for diversification, tax, or planned spending; also, the stock’s valuation metrics (negative P/E) suggest fundamentals may be the dominant driver.

Relevance 8/10Novelty 6/10Timing: SEC-disclosed insider sale dated May 26 (reported May 30).

Background

The piece centers on an SEC-reported insider transaction (director selling) and adds recent earnings context (EPS $0.04; revenue $9.42M) plus an analyst rating update (upgraded within Sell range).

Company-level read

Ticker impact

$BYFCBearishMedium confidence
Context

BYFC director Wayne-Kent Bradshaw sold 8,600 shares at an average $9.42, reducing his stake by 20.5% per SEC disclosure.

Expected impact

Near-term bias modestly negative; follow-through depends on next earnings/credit performance rather than the sale alone.

Evidence & confidence

The article provides a concrete Form 4-style sale and mentions recent EPS/revenue context, but no new guidance or deal/credit event is introduced.

Market effects

For small savings-and-loan banks, insider trimming can slightly pressure sentiment, but sector-wide read-across is limited without regulatory/credit news.

Limited—article is company-specific to a Southern California-focused bank holding company.

Low—no macro, rates shock, or cross-border event is cited.

Counterpoint

Insider sales can be routine liquidity/portfolio rebalancing and don’t necessarily signal deterioration in loan/credit quality.

Key entities

  • Broadway Financial Corporation

    NASDAQ-listed savings-and-loan bank holding company; subject of the insider selling disclosure.

  • Wayne-Kent Bradshaw

    Director who sold 8,600 shares at an average $9.42, trimming ownership by 20.5%.

  • Weiss Ratings

    Upgraded BYFC from Sell (d) to Sell (d+), indicating still-cautious stance.

  • M3F Inc.

    Raised its stake in BYFC via a 13F increase during the third quarter.

Related articles

$BYFCMed

Broadway Financial Corporation Reports Second Quarter 2026 Results Reflecting Strong Loan and Deposit Growth and Enhanced Operating Performance

BROADWAY FINANCIAL CORP \DE\ (BYFC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20078897_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 News Release FOR IMMEDIATE RELEASE Broadway Financial Corporation Reports Second Quarter 2026 Results Reflecting Strong Loan and Deposit Growth and Enhanced Operating Performance LOS ANGELES, CA – (BUSINESS WIRE) – July 28

$GMABMedAI 8/10

Genmab reports trial results for ovarian cancer drug candidate

Genmab (GMAB) reported Phase 1/2 trial results for rinatabart sesutecan in platinum-resistant ovarian cancer, showing a 45.9% response rate and median progression-free survival of 9.5 months. The trial involved 109 patients, with common side effects including fatigue, nausea, and anemia. The drug is being evaluated in four Phase 3 trials for various gynecologic cancers.

$RKLBMed

Rocket Lab Just Signed the Biggest Commercial Electron Deal in Its History. Its Launch Backlog Now Tops 100.

Rocket Lab (RKLB) secured a 20-launch deal with Synspective, its largest commercial contract, boosting its backlog to over 100 missions. Synspective's total orders now reach 47 Electron missions. The stock rose 6% post-announcement, but concerns about competition from SpaceX persist. Rocket Lab's revenue per launch increased to $9.2M in H1 2026, with costs dropping to $4.9M.

$AMZNMed

Amazon is discussing selling $8 billion worth of Nvidia chips to investors and leasing them back.

Amazon is considering a deal to sell $8B of Nvidia Grace Blackwell chips to an SPV, then lease them back. The chips are for AI systems in Amazon's data centers. Investors may finance the SPV, with Amazon potentially offering a 10% stake. The arrangement aims to separate ownership from usage, reducing Amazon's capital expenditure. Nvidia and Amazon have not commented. According to the Financial Times, the deal is not finalized.